Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Mar 14
Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026 Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time. Duyuru • Feb 04
Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management Company Cosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group. Duyuru • Apr 30
Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025 Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025. Duyuru • Apr 01
Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal Counsel Cosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy). Duyuru • Feb 11
Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI Officer Cosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy. Duyuru • Jan 08
Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025 Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025 Duyuru • Oct 12
Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer Changes Cosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo. Reported Earnings • Jul 29
First half 2024 earnings released: EPS: €4.72 (vs €0.092 in 1H 2023) First half 2024 results: EPS: €4.72 (up from €0.092 in 1H 2023). Revenue: €136.2m (up 212% from 1H 2023). Net income: €76.0m (up €74.5m from 1H 2023). Profit margin: 56% (up from 3.4% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Jul 28
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Jul 03
Upcoming dividend of €2.00 per share Eligible shareholders must have bought the stock before 10 July 2024. Payment date: 12 July 2024. The company is not currently making a profit and its cash payout ratio is 92%. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.2%). Duyuru • Apr 28
Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy. New Risk • Mar 24
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin). Duyuru • Mar 22
Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024 Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024 Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022) Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Duyuru • Feb 15
Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024 Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024 Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €51.00, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 30% over the past three years. Reported Earnings • Jul 28
First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022) First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 24
Upcoming dividend of €1.05 per share at 2.0% yield Eligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.5%). Reported Earnings • Mar 24
Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021) Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Jul 29
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2022 The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Breakeven Date Change • Sep 23
Forecast to breakeven in 2021 The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule. Breakeven Date Change • Aug 04
Forecast breakeven moved forward to 2021 The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule. Reported Earnings • Aug 02
First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Executive Departure • Jun 04
Non-Executive Director Hans Tanner has left the company On the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years. Duyuru • Mar 27
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2021 Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2021. For the year, the company’s revenues to be in the range of €60 million to €64 million and operating profit to be in the range of €3 million to €5 million. Reported Earnings • Mar 27
Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 06
New 90-day low: €71.50 The company is down 7.0% from its price of €76.60 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Duyuru • Feb 18
Cosmo Pharmaceuticals Strengthens Partnership with RedHill Biopharma with Manufacturing Agreement for Movantik, RHB-204 and Opaganib Cosmo Pharmaceuticals NV announced an agreement with RedHill Biopharma Ltd. to manufacture three key products; Movantik® (RedHill's selling product in the U.S.), RHB-204 (currently in a Phase III U.S. study as a stand-alone first-line treatment for pulmonary nontuberculous mycobacteria (NTM) disease) and opaganib (a new, orally-administered, chemical entity currently in a global Phase II/III study for treatment of COVID-19 pneumonia). These agreements provide secure high-quality manufacturing capacity for all three products. Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the U.S. specifically designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain1. OIC is the most common and debilitating gastrointestinal adverse effect associated with opioid therapy, estimated to affect between 40-80% of the millions of patients taking chronic opioid therapy each year. RHB-204 is RedHill's investigational proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed as a stand-alone first-line treatment for pulmonary NTM disease caused by Mycobacterium avium Complex (MAC). Although rare, the incidence and prevalence of pulmonary NTM disease are increasing in many areas of the world. There were an estimated 110,000 pulmonary NTM disease patients in the U.S. in 2017, with U.S. market potential estimated at over USD 500 million. RHB-204 has received FDA Fast Track, Orphan Drug and QIDP designations aimed at accelerating development and FDA review and extending U.S. market exclusivity to a potential total of 12 years, to be granted at the time of FDA approval. Opaganib is being evaluated by RedHill as a treatment for COVID-19 pneumonia in a global Phase II/III study and has demonstrated positive safety and efficacy top-line data from a U.S. Phase II study. Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component of viral replication, potentially minimizing the likelihood of viral resistance. It has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications. Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is also being evaluated in a Phase IIa study in advanced cholangiocarcinoma and in a Phase II study in prostate cancer. Duyuru • Feb 06
Alfasigma Spa Enters into Licensing Agreement to Distribute Lumeblue™ in the Eu with Cosmo Pharmaceuticals Alfasigma Spa announced that it has finalized a licensing agreement to distribute Lumeblue™ in the EU with Cosmo Pharmaceuticals. Lumeble™ was recently approved by EMA for the detection of lesions during colonoscopy. Cosmo will receive a €4 million upfront payment from Alfasigma, plus double-digit royalties and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™. Is New 90 Day High Low • Feb 06
New 90-day high: €80.00 The company is up 8.0% from its price of €74.20 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. Duyuru • Feb 05
Cosmo Pharmaceuticals NV Announces License of Lumeblue EU Rights to Alfasigma Cosmo Pharmaceuticals NV announced that it has licensed the EU rights (plus Switzerland, UK, EEA countries, Russia and Mexico) for Lumeblue™ to Alfasigma S.p.A. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy. Duyuru • Jan 29
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals RedHill Biopharma Ltd. announced a manufacturing agreement with Cosmo Pharmaceuticals NV to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640)1, to address prospective demand subsequent to potential global emergency use authorizations. The global Phase 2/3 study of opaganib in severe COVID-19 pneumonia (NCT04467840) is ongoing, with patients enrolled in more than 30 sites in multiple countries. An interim independent Data and Safety Monitoring Board (DSMB) futility analysis will be conducted in the coming days, evaluating data from the first 135 subjects that have reached the primary endpoint. The study has previously undergone two unblinded independent DSMB safety data reviews, with unanimous recommendations to continue the study. Preliminary data from a non-powered U.S. Phase 2 study of 40 hospitalized patients recently showed that opaganib was safe and demonstrated greater improvement in reducing oxygen requirement by end of treatment on Day 14 across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal scale. Duyuru • Jan 12
Cosmo Pharmaceuticals N.V Announces Successful Outcome of Rifamycin 600Mg Phase II trial in IBS-D Cosmo Pharmaceuticals N.V announced the successful outcome of its Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D). The drug tested is different from Aemcolo®/Relafalk®, which is already approved for Traveler's Diarrhea: while it shares the same active ingredient (Rifamycin SV) and MMX technology, it contains a higher dose of API (600mg) and different release features. The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up. The primary endpoint was the proportion of subjects who achieved success, defined as an adequate relief of both abdominal pain and diarrhea at the end of the first week of treatment (at least 30% decrease in pain score and at least 50% reduction in the number of days per week with diarrhea). Other endpoints included reduction in bloating, improved stool consistency, decreased sense of urgency, and improvement in quality of life as assessed through the IBS QoL questionnaire. The trial was conducted in 25 sites located in 4 countries in Western Europe and recruited 279 patients in the ITT ("Intention to treat") population. The trial was very successful notwithstanding the decision by Cosmo to reduce the envisaged sample size by 20% due to COVID-19 restrictions. Results show the achievement of statistical significance in all the study populations (ITT, FAS, m-FAS and PP) for the composite primary endpoint (substantial pain and diarrhea decrease) [OR 3.26 (1.39 - 7.67); p-value 0.0066] and for most secondary endpoints such as adequate relief of IBS-related symptoms [OR 2.18 (1.12 - 4.26); p-value 0.0227 ] and IBS-related bloating at the end of treatment period [OR 2.13 (1.11 - 4.07); p-value 0.0223]. Duyuru • Dec 15
Cosmo Pharmaceuticals Announces Amendment of Its Investment Agreement with Acacia Cosmo Pharmaceuticals N.V. announced that, on 14 December 2020, Acacia Pharma Group plc and Cosmo entered into an amendment agreement (the "Amendment Agreement") being an amendment to the Investment Agreement between the parties dated 10 January 2020, pursuant to which Acacia and Cosmo agreed that, in exchange for Cosmo prioritising the packaging and labelling production run for BYFAVOTM for supply in the US, Acacia shall make the EUR 5 million payment due on the first commercial sale of BYFAVOTM in advance of the first commercial sale of BYFAVOTM and by no later than 31 December 2020. Acacia Pharma is preparing to launch BYFAVOTM in the US in the coming weeks. Payment will be settled by the Company issuing new ordinary shares in the share capital of the Company (the "New Ordinary Shares") to Cosmo, at an issue price of EUR 2.38 each (being the 15-day volume weighted average price of the Company's shares prior to the date of the Amendment Agreement). Listing and admission to trading of the New Ordinary Shares on Euronext Brussels remains, in accordance with the Investment Agreement, conditional upon the necessary regulatory approvals being obtained from the FCA and the Belgian FSMA. 
